Board of Directors
IPM’s Board of Directors (BOD) oversees the organization’s strategic planning, operations and finances.
Board members have extensive experience in public health, HIV prevention, pharmaceutical development, economic development, health care financing, and government operations in both developing and developed countries.
The current Board is composed of 12 members, representing countries in Africa, Asia, Europe and North America, who work in academia, government, and the for-profit and nonprofit private sectors.
Each member serves on a volunteer basis for three-year terms. IPM’s chief executive officer serves as an ex officio nonvoting member of the Board.
Scientific Advisory Board
IPM's Scientific Advisory Board (SAB) was created in 2002 to provide ongoing, high-level scientific advice to IPM’s staff and BOD.
Our scientific agenda is based on a set of decision-making criteria first approved by the SAB in 2003. The original SAB did not meet regularly, but IPM established an Executive Committee of its SAB to convene annually, beginning in 2006.
Beginning in 2009, the SAB created two subcommittees, with ad hoc subcommittees to be formed if product development and clinical activities and timelines require more defined expert discussion.
The SAB is composed of members with expertise in drug development, HIV and ARV science, microbicide development, clinical evaluation, delivery system expertise, regulatory knowledge and other relevant areas.
IPM’s Board of Directors reviews, approves and updates, as needed, the “Terms of Reference for the SAB,” and is consulted on SAB composition and leadership.